A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
Antineoplastic Combined Chemotherapy Protocols
Histone Deacetylase Inhibitors
Oral panobinostat with and without docetaxel is feasible, and docetaxel had no apparent effect on the pharmacokinetics of panobinostat. Since preclinical studies suggest a dose-dependent effect of panobinostat on PSA expression, and other phase I data demonstrate that intravenous panobinostat produces higher peak concentrations (>20- to 30-fold) and area under the curve (3.5x-5x), a decision was made to focus the development of panobinostat on the intravenous formulation to treat CRPC.